With healthier finances, Clover Bio shifts to flu and RSV vaccines
The Chinese vaccine developer rebounded from a deep loss into profit in the first half of the year, boosted by a one-off gain from a Covid research grant Key Takeaways:…
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
The innovative drug maker has been approved to sell two more cancer drugs in China, but that hasn’t lifted its stock price Key Takeaways: Innovent Bio has brought several drugs…
CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment
CStone’s executive reshuffle comes after company discovers questionable investment made by finance vice president in 2021 Key Takeaways: CStone brought four products to market last year, and its losses have…
Connect Biopharma’s Latest Dermatitis Drug Update Fails to Pump Up Shares
Company’s stock sank after it released data on Phase 2b trials for its atopic dermatitis drug, a potential competitor to Regeneron-Sanofi blockbuster Dupixent Key takeaways: Loss-making Connect Biopharma says Phase…
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
